Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
Abstract: Disclosed are histone deacetylase (HDAC) inhibitors, or combinations comprising an HDAC inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of chronic lymphocytic leukemia in a subject in need thereof. Also provided herein are methods for treating chronic lymphocytic leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor. Other related methods are disclosed.
Type:
Grant
Filed:
April 19, 2017
Date of Patent:
November 14, 2023
Assignees:
ACETYLON PHARMACEUTICALS, INC., H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
Inventors:
Simon S. Jones, Steven N. Quayle, Eva Sahakian, Javier Pinilla Ibarz
Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a BCL-2 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
Abstract: The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.
Type:
Grant
Filed:
August 26, 2019
Date of Patent:
April 4, 2023
Assignee:
Acetylon Pharmaceuticals, Inc.
Inventors:
John H. van Duzer, Ralph Mazitschek, Walter Ogier, James E. Bradner, Guoxiang Huang, Dejian Xie, Nan Yu
Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
November 15, 2022
Assignee:
ACETYLON PHARMACEUTICALS, INC.
Inventors:
Steven Norman Quayle, Simon Stewart Jones, Teru Hideshima, Kenneth C. Anderson
Abstract: Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.
Type:
Application
Filed:
March 22, 2022
Publication date:
September 15, 2022
Applicants:
ACETYLON PHARMACEUTICALS, INC., ACETYLON PHARMACEUTICALS, INC.
Inventors:
Steven Norman Quayle, Jeffrey R. Shearstone
Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
Type:
Grant
Filed:
November 22, 2017
Date of Patent:
May 24, 2022
Assignee:
Acetylon Pharmaceuticals, Inc.
Inventors:
Steven Norman Quayle, Simon Stewart Jones, Teru Hideshima, Kenneth C. Anderson
Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a CD20 inhibitory antibody for the treatment of a B-cell disorder, such as cancer, in a subject in need thereof. Also provided herein are methods for treating a B-cell disorder in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a CD20 inhibitory antibody.
Type:
Grant
Filed:
August 7, 2017
Date of Patent:
May 10, 2022
Assignee:
Acetylon Pharmaceuticals Inc.
Inventors:
Simon Steward Jones, Chengyin Min, Steven Norman Quayle
Abstract: Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.
Type:
Grant
Filed:
February 17, 2017
Date of Patent:
April 26, 2022
Assignee:
ACETYLON PHARMACEUTICALS, INC.
Inventors:
Steven Norman Quayle, Jeffrey R. Shearstone
Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a BET inhibitor for the treatment of cancer in a subject in need thereof. Also provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a BET inhibitor.
Type:
Grant
Filed:
June 9, 2017
Date of Patent:
April 12, 2022
Assignees:
DANA-FARBER CANCER INSTITUTE, INC., ACETYLON PHARMACEUTICALS, INC.
Inventors:
Kwok-kin Wong, Yan Liu, Dennis O. Adeegbe, Steven Norman Quayle
Abstract: The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a BET inhibitor for the treatment of cancer in a subject in need thereof. Also provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a BET inhibitor.
Type:
Application
Filed:
June 9, 2017
Publication date:
October 15, 2020
Applicants:
DANA-FARBER CANCER INSTITUTE, INC., ACETYLON PHARMACEUTICALS, INC., ACETYLON PHARMACEUTICALS, INC.
Inventors:
Kwok-kin WONG, Yan LIU, Dennis O. ADEEGBE
Abstract: The invention relates to combinations comprising an HDAC inhibitor and a Her2 inhibitor for the treatment of breast cancer in a subject in need thereof. The invention also relates to combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need thereof. Also provided herein are methods for treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations. Further provided are methods for inhibiting migration and/or invasion of a breast cancer cell in a subject by administering to the subject a HDAC6 specific inhibitor.
Type:
Grant
Filed:
June 22, 2016
Date of Patent:
July 28, 2020
Assignee:
Acetylon Pharmaceuticals, Inc.
Inventors:
David Lee Tamang, Min Yang, Simon S. Jones
Abstract: The invention relates to methods for using biomarkers to identify cancer patients that will or are likely to respond to treatment. Specifically, the invention relates to the use of one or more of three association studies of cancer types, gene mutations, or gene expression levels in order to identify cancer patients that will or are likely to respond to treatment with a histone deacetylase (HDAC) inhibitor, alone or in combination with another cancer treatment. The methods may, optionally, further include treating such patient with an HDAC inhibitor, alone or in combination with another cancer treatment.
Abstract: This disclosure provides solid forms of 2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide, and methods of manufacturing and using these forms.
Type:
Grant
Filed:
June 8, 2016
Date of Patent:
November 5, 2019
Assignee:
ACETYLON PHARMACEUTICALS, INC.
Inventors:
John H. van Duzer, Farzaneh Seyedi, Gui Liu
Abstract: The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
Abstract: The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of lymphoma in a subject in need thereof. Also provided herein are methods for treating lymphoma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.
Type:
Grant
Filed:
December 3, 2014
Date of Patent:
April 24, 2018
Assignee:
ACETYLON PHARMACEUTICALS, INC
Inventors:
Steven Norman Quayle, Simon Stewart Jones
Abstract: The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.